Previous 10 |
home / stock / onc:cc / onc:cc news
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort Canada NewsWire First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated ...
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity New insights into pelareorep's immune-related mechanism of action demonstrate it stimulates an innate immune response...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONC:CC Stock Symbol:
TSXC Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program PR Newswire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence PR Newswire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...